8-K: The Oncology Institute Amends Facility Agreement, Pays Down $20 Million in Debt

The Oncology Institute (TOI) announces an amendment to its facility agreement with Deerfield Management, including a $20 million debt paydown and the removal of a minimum cash covenant.

Summary

• The Oncology Institute, Inc. (TOI) has amended its existing facility agreement with Deerfield Partners, L.P.
• The amendment includes a partial prepayment of approximately $20 million of senior secured convertible notes, along with accrued and unpaid interest.
• Deerfield has agreed to waive certain restrictions on TOI's ability to offer and sell equity and equity-linked securities.
• The financial covenant requiring TOI to hold at least $40 million in cash or cash equivalents has been removed.
• TOI has signed three new capitation agreements year-to-date, adding approximately 80,000 lives across California, Nevada, and Florida markets.
• Total lives in Florida under value-based agreements now exceed 200,000, with over 50,000 under Medicare Advantage.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the debt paydown, increased financial flexibility, and growth in capitation agreements. However, the presence of forward-looking statements and associated risks tempers the overall optimism.

Positives

• The amendment to the facility agreement strengthens TOI's financial position.
• The removal of the $40 million minimum cash covenant provides TOI with greater financial flexibility.
• The ability to offer and sell equity and equity-linked securities provides TOI with potential access to capital.
• The debt paydown reduces TOI's financial obligations.
• The addition of 80,000 lives through new capitation agreements expands TOI's market reach.
• The growth of value-based agreements in Florida demonstrates TOI's success in this market.

Risks

• The press release includes forward-looking statements that are subject to risks and uncertainties.
• These risks and uncertainties could cause actual results to differ materially from the results implied by these forward-looking statements.
• These risks include the outcome of judicial and administrative proceedings, changes in patient or payor preferences, and the impact of COVID-19.

Future Outlook

The company aims to strengthen its financial position and focus on accelerating growth initiatives.

Management Comments

• Daniel Virnich, CEO of TOI, stated that the agreement with Deerfield strengthens the company's financial position and allows them to focus on accelerating growth initiatives.
• He expressed gratitude for Deerfield's ongoing support and collaboration.

Industry Context

The announcement reflects a trend in the healthcare industry towards value-based care models and strategic financial partnerships to support growth and innovation.

Comparison to Industry Standards

• The Oncology Institute's focus on value-based care aligns with industry trends, similar to companies like Oak Street Health (OSH) and ChenMed, which also focus on providing comprehensive care to specific patient populations.
• The debt paydown and amendment to the facility agreement are strategic moves to improve financial flexibility, similar to actions taken by other healthcare companies to optimize their capital structure.
• The addition of 80,000 lives through new capitation agreements is a positive indicator of growth, comparable to the expansion strategies of other healthcare providers in the value-based care space.

Stakeholder Impact

• Shareholders: The amendment and debt paydown could positively impact shareholder value by improving the company's financial stability and growth prospects.
• Employees: The focus on growth initiatives could create new opportunities for employees.
• Patients: The expansion of value-based care models could improve patient access to quality cancer care.
• Lenders: The prepayment of debt reduces the company's financial obligations to lenders.

Next Steps

• The Borrower shall file an Amendment to the Certificate of Designation (the Certificate of Designation Amendment) with the Secretary of State of the State of Delaware to increase the number of shares designated as Preferred Stock to such number of shares as is necessary to allow for the issuance of all of the Participation Securities and shall cause the Certificate of Designation Amendment to become effective prior to the consummation of the first Equity Offering and remain effective at all times thereafter (including following each and every Equity Offering).
• The Borrower shall, in connection with each Equity Offering, submit an application for the listing on the Principal Market of the Additional Securities and the Participation Securities sold in such Equity Offering (the Nasdaq Listing Application) and will use its reasonable best efforts to secure such listing.

Key Dates